Cargando…

Longitudinal follow‐up and performance validation of an mRNA‐based urine test (Xpert(®) Bladder Cancer Monitor ) for surveillance in patients with non‐muscle‐invasive bladder cancer

OBJECTIVE: To evaluate the performance of the Xpert Bladder Cancer Monitor (Xpert; Cepheid, Sunnyvale, CA, USA) test as a predictor of tumour recurrence in patients with non‐muscle‐invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients (n = 429) undergoing surveillance for NMIBC underwent X...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cowan, Barrett, Klein, Eric, Jansz, Ken, Westenfelder, Karl, Bradford, Timothy, Peterson, Chad, Scherr, Douglas, Karsh, Lawrence I., Egerdie, Blair, Witjes, Alfred, Trainer, Andrew, Harris, Richard, Goldfarb, Bernard, Flax, Stanley, Kroeger, Robert, Boyd, Buffi, Liao, Joseph, Patel, Sanjay, Bridge, Julia, Reuter, Victor, Quigley, Neil, Brown, Sarah, Zhao, Suling, Satya, Malini, Bates, Michael, Simon, Iris M., Campbell, Scott, Lotan, Yair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292663/ https://www.ncbi.nlm.nih.gov/pubmed/33793062 http://dx.doi.org/10.1111/bju.15418

Ejemplares similares

Editorial: Identifying novel biomarkers in bladder cancer
por: Ecke, Thorsten H., et al.
Publicado: (2023)

Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under “Active Surveillance” for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study
por: Fasulo, Vittorio, et al.
Publicado: (2022)

Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer
por: Clinton, Timothy, et al.
Publicado: (2017)

Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer
por: Youssef, Ramy F., et al.
Publicado: (2011)

Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer
por: Karsh, Lawrence, et al.
Publicado: (2018)

Pooled analysis of Xpert Bladder Cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma
por: Liu, Ye-Ling, et al.
Publicado: (2021)

The Performance of the Xpert Bladder Cancer Monitor Test and Voided Urinary Cytology in the Follow-up of Urinary Bladder Tumors
por: Smrkolj, Tomaz, et al.
Publicado: (2020)

Comment on “Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma”
por: Sharma, Gopal
Publicado: (2021)

Molecular markers in bladder cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts
por: Tse, Jennifer, et al.
Publicado: (2019)

Response to comment on “Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma”
por: Xie, Yu-Fei, et al.
Publicado: (2022)

Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
por: Lozano, Fernando, et al.
Publicado: (2023)

Diagnostic value of Xpert(®) Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update
por: D’Elia, Carolina, et al.
Publicado: (2021)

Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer
por: Sahu, Divya, et al.
Publicado: (2017)

Topic issue on new treatments in bladder cancer
por: Witjes, J. A.
Publicado: (2009)

Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up
por: Cancel-Tassin, G., et al.
Publicado: (2021)

Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging
por: Vanarsa, Kamala, et al.
Publicado: (2023)

Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)
por: Breyer, Johannes, et al.
Publicado: (2023)

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
por: Aydin, Ahmet Murat, et al.
Publicado: (2017)

Follow-up in non-muscle invasive bladder cancer: facts and future
por: Witjes, J. Alfred
Publicado: (2020)

Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer
por: Witjes, J Alfred, et al.
Publicado: (2021)

Expression of the Long Non-Coding RNA HOTAIR Correlates with Disease Progression in Bladder Cancer and Is Contained in Bladder Cancer Patient Urinary Exosomes
por: Berrondo, Claudia, et al.
Publicado: (2016)

Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours
por: Roumiguié, Mathieu, et al.
Publicado: (2020)

Experimental rat bladder urothelial cell carcinoma models
por: Arentsen, Harm C., et al.
Publicado: (2009)

Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens
por: Vanarsa, Kamala, et al.
Publicado: (2021)

Xpert® bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results
por: D’Elia, Carolina, et al.
Publicado: (2022)

Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer
por: Vantaku, Venkatrao, et al.
Publicado: (2017)

The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis
por: van der Heijden, Antoine G., et al.
Publicado: (2007)

Bladder Cancer Biomarker Discovery Using Global Metabolomic Profiling of Urine
por: Wittmann, Bryan M., et al.
Publicado: (2014)

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer
por: Masuda, Norihiko, et al.
Publicado: (2018)

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
por: Hurle, Rodolfo, et al.
Publicado: (2020)

Correction: Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer
por: Vantaku, Venkatrao, et al.
Publicado: (2019)

The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT© Bladder Cancer Monitor and Narrow Band Imaging© Cystoscopy
por: Singer, Gad, et al.
Publicado: (2022)

Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model
por: Falke, J., et al.
Publicado: (2018)

Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer
por: Schuettfort, Victor M., et al.
Publicado: (2021)

Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer
por: Kittler, Ralf, et al.
Publicado: (2018)

Lipidomic Profiling Identifies a Novel Lipid Signature Associated with Ethnicity-Specific Disparity of Bladder Cancer
por: Kami Reddy, Karthik Reddy, et al.
Publicado: (2022)

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
por: Xylinas, E, et al.
Publicado: (2013)

Translation and validation of two disease-specific patient-reported outcome measures (Bladder Cancer Index and FACT-Bl-Cys) in Dutch bladder cancer patients
por: Michels, Charlotte T. J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ubn4vcporgbqagptl3fdhpd5gh